MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Cencora, Inc. (COR), formerly, AmerisourceBergen Corporation (NYSE:ABC)*
Organization & Developments: AmerisourceBergen
Parents
Cencora, Inc. (COR), formerly, AmerisourceBergen Corporation (NYSE:ABC)*
Children
*Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001
*DISTRIBUTES BRAND NAME AND GENERIC DRUGS, OVER-THE-COUNTER HEALTHCARE PRODUCTS AND HOME HEALTHCARE SUPPLIES
*Pharmaceutical distribution and services company
*Pharmaceutical Wholesaler
2015: ObamaCare, Generic Drugs Boost AmerisourceBergen ABC MYL LCI WBA
2022: AmerisourceBergen Corporation 2022 Q4 - Results - Earnings Call Presentation_seekingalpha.com
2022: AmerisourceBergen Corporation: Looking Healthier_seekingalpha.com
2022: AmerisourceBergen launches $150M venture fund for emerging healthcare companies
2022: The company has supported a handful of Covid treatments, including Eli Lilly's antibody bamlanivimab, Gilead's antiviral Veklury, and Merck and Ridgeback's molnupiravir
2022: The company's US revenue reached $53.4 billion last quarter, up 6% from the same period last year.
2023: AmerisourceBergen Screams Quality At 15x Earnings, 60% ROIC_seekingalpha.com
2024: Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating
2024: DLA_AmerisourceBergen Drug Corp., has been awarded an estimated $2,031,406,952 modification (P00032) extending the third two-year six-month option period of a two-year six-month base contract (SPE2DX-15-D-1000) with three two-year six-month option periods for prime vendor pharmaceutical and pharmaceutical-related products and support.
2025: Cencora: Higher Potential Returns After Reduced Walgreens Stake
2025: DLA_AmerisourceBergen Drug Corp., (SPE2DX-25-D-1000 $5,649,602,820), DMS Pharmaceutical Group Inc., (SPE2DX-25-D-9000, $277,666,966), and Cardinal Health Inc., (SPE2DX-25-D-8000, $16,564,367), have each been awarded a firm-fixed-price requirements contract under solicitation SPE2DX-24-R-0001 for pharmaceutical and pharmaceutical-related products.
Jumps
*Key People: AmerisourceBergen
Finance & Acquisitions: AmerisourceBergen